Benefits and risk assessment
PD, glioma, tumor, abemaciclib
TUMOR, BRAIN STEM GLIOMA, GLIOMA, TUMOR GROWTH, METASTATIC BREAST CANCER
Previous studies evaluating overall response rates post treatment in brain stem gliomas have demonstrated some efficacy in inhibition of the CDK pathway. Abemaciclib (Verzenio®) is a CDK4/6 inhibitor drug that is FDA approved for advanced or metastatic breast cancer. Previous studies using high grade glioma xenograft models treated demonstrated the ability of abemaciclib to cross the BBB, increase survival, and decrease tumor growth when given as a single agent or in combination with temozolomide. The potential benefits from this therapy are identification of targetable genetic alterations which can be matched with potential therapeutics for maintenance therapy post radiation. These therapies have the potential to stabilize or reduce tumor burden post radiation.There are risks associated with abemaciclib administration and surgical biopsy/resection and microdialysis placement, however we believe the potential benefits of treating targetable tumor PK and PD findings outweigh the risks.